Acupuncture for the treatment of severe acute pain in Herpes Zoster: results of a nested, open-label, randomized trial in the VZV Pain Study
- Tamara Ursini†1,
- Monica Tontodonati†1,
- Lamberto Manzoli†2,
- Ennio Polilli1,
- Cristina Rebuzzi3,
- Gabriele Congedo4,
- Sonia Di Profio3,
- Patrizia Marani Toro5,
- Augusta Consorte1,
- Giuseppina Placido1,
- Stefano Laganà4,
- Claudio D'Amario5,
- Carla Granchelli5,
- Giustino Parruti1Email author,
- Lucio Pippa4 and
- the VZV Pain Study Group
© Ursini et al; licensee BioMed Central Ltd. 2011
Received: 20 December 2010
Accepted: 5 June 2011
Published: 5 June 2011
Data on the potential efficacy of acupuncture (AC) in controlling intense or very intense pain in patients with Herpes Zoster (HZ) has not been so far adequately assessed in comparison with standard pharmacological treatment (ST) by a controlled trial design.
Within the VZV Pescara study, pain was assessed in HZ patients on a Visual Analogue Scale (VAS) and by the McGill Pain Questionnaire (MPQ) both at the beginning and at the end of treatment. Response rates, mean changes in pain intensity, differences in total pain burden with an area-under-the-curve (AUC) method over a 1-year follow-up and differences in the incidence of Post-Herpetic Neuralgia (PHN) were evaluated.
One hundred and two patients were randomized to receive either AC (n = 52) or ST (n = 50) for 4 weeks. Groups were comparable regarding age, sex, pain intensity at presentation and missed antiviral prescription. Both interventions were largely effective. No significant differences were observed in response rates (81.6% vs 89.2%, p = 0.8), mean reduction of VAS (4.1 +/- 2.3 vs 4.9 +/- 1.9, p = 0.12) and MPQ scores (1.3 +/- 0.9 vs 1.3 +/- 0.9, p = 0.9), incidence of PHN after 3 months (48.4% vs 46.8%, p = 0.5), and mean AUC during follow-up (199 +/- 136 vs 173 +/- 141, p = 0.4). No serious treatment-related adverse event was observed in both groups.
This controlled and randomized trial provides the first evidence of a potential role of AC for the treatment of acute herpetic pain.
A significant proportion (18% to 41%) of patients suffering with Herpes Zoster (HZ) experience intense or very intense pain at presentation, frequently persisting after the healing of rash [1–4]. Both pain in the acute phase and chronic pain in post-herpetic neuralgia (PHN) may severely impact on quality of life and health care costs, interfering with physical, emotional and social functioning of affected patients [5–7]. Therefore, several investigations were carried out to identify effective strategies to control Zoster-related pain [8–11].
Current therapeutic options include the repeated administration of paracetamol and/or other NSAIDs for the immediate relief of pain [9, 10], antiviral drugs, which accelerate the resolution of acute pain and may reduce the incidence of PHN [12–14], long-term gabapentinoids and local anaesthesia for selective nerve blockade in patients with intense or very intense pain at presentation [15–21]. Finally, opioid analgesics, including tramadol, possibly combined with other neuroactive agents, such as amitriptyline, have been used in the event of unresponsive pain [22–26]. In the most suffering patients, however, the control of pain is often unsatisfactory despite the administration of complex drug combinations, which also bear the potential of relevant metabolic effects [11, 22].
In this context, the evidence that acupuncture may be efficacious in the treatment of neuropathic pain syndromes lead to the hypothesis of a potential beneficial effect of this procedure for acute HZ-related pain [27–29]. Therefore, several studies investigated the impact of acupuncture in patients with intense pain due to HZ or PHN, with controversial results [13, 30–35]. None of them, however, was a randomized controlled trial for acute pain in HZ [13, 36, 37].
Here we report on a randomized, controlled trial, comparing the efficacy of acupuncture (AC) and standard pharmacological treatment (ST) in controlling intense or very intense acute pain in patients with HZ.
Study design and population
The present randomized clinical trial was nested within the "VZV Pescara Study", a cohort study aimed at evaluating the intensity of pain at presentation, pain persistence, overall pain burden and relative predictors in HZ patients . Final approval of the study was granted by the Ethical Committee of the Local Healthcare Agency of Pescara in March, 2006. From May 2006 to April 2008, 41 General Practitioners (GPs) in the district of Pescara, Italy, the Infectious Diseases (ID) Unit, the Dermatology Unit, and Pain Management Clinic (PMC) of the Pescara General Hospital asked all incident cases of HZ to participate in the cohort study. All data were collected by the Infectious Disease Unit using a specifically created computerized network. All eligible patients granting signed informed consent were followed for 12 months. Patients enrolled in the cohort study with pain classified as intense or very intense on a five-degree semi-quantitative scale (no pain, mild, moderate, intense, very intense) were asked to participate in the present trial. At enrolment, a second specific informed consent was obtained, and the intensity of pain was re-assessed using a Visual Analogue Scale (VAS) [38, 39]. If the intensity was ≥ 7 at VAS, participants were randomized to receive either standard pharmacological treatment (ST) or acupuncture (AC). The randomization process was carried out by the Statistical Unit and stratified by gender, age class (10 y) and pain intensity (VAS 7-8, and VAS 9-10). None of the investigators had any role in the allocation of patients.
The main outcome of the study was the reduction in pain intensity between baseline and the end of the 4-week treatment, as measured by the reduction in the VAS score [38, 39]. Secondary outcomes included: the reduction in the score of the McGill Pain Questionnaire (MPQ), which was administered by a psychologist for the multidimensional definition of pain in the individual patient [39–41]; the response rate (VAS score decrease by at least 2 points during treatment); the percentage of incident cases of PHN (defined as the presence of pain of any grade 3 months after enrolment - data obtained from the nesting cohort study); the total pain burden during the 12-month follow-up of the cohort study; finally, the incidence of treatment-related serious adverse events during treatment (grade 3 or higher according to the WHO scale) . The total pain burden was quantified using an area-under-the-curve (AUC) method [14, 43]. In brief, all patients in the cohort study were asked about pain severity at 1, 3, 6 and 12 months after enrolment, using the five-degree semi-quantitative scale described above. To obtain the AUC, measures of pain intensity were combined with pain duration, and each patient's AUC was calculated as the sum of all areas obtained by multiplying the average of 2 consecutive pain scores by the number of days between the scores.
Sample size estimation
Because of the recent debate on non-inferiority trials , the study was conservatively planned with a superiority design. As mentioned above, the main outcome was the difference in the mean change of VAS scores from baseline to the end of the treatment between groups. According to previous studies [30–35] and inclusion criteria, the expected baseline mean VAS score was 8.0 ± 2.0 in both groups. The expected mean score at the end of the follow-up was 2.5 ± 2.0 in the acupuncture group; 4.0 ± 2.0 in the control group, with mean changes from baseline of 5.5 (2.0) and 4.0 (2.0), respectively. Using an unpaired t-test, and assuming an alpha-error = 0.05 and an expected withdrawal/dropout rate of 20%, a minimum of 34 subjects per group were requested to achieve a 80% statistical power.
Kruskal-Wallis test was used to compare VAS, McGill and AUC mean scores across groups at each time point, as well as the mean change in each score during the follow-up. Chi-squared test was used to compare the VAS response rate and the prevalence of PHN between groups. Within each group, the differences in VAS and McGill scores between baseline and the end of the 4-week treatment were evaluated using paired t-test and confirmed through the Wilcoxon matched-pairs signed ranks test. A two-tailed p-value of 0.05 was considered significant for all analyses, which were carried out using Stata 10.1 (Stata Corp., College Station, TX, 2007).
Characteristics of the sample
Demographic and clinical characteristics of treated patients, by group.
Standard Therapy (n = 32)
Acupuncture (n = 34)
Male gender, %
Mean age in years (SD)
Current smoking, %
High-school or higher educational level, %
Depression (clinical diagnosis), %
Missed antiviral prescription, %
Very intense pain at presentation, %
Vesicles (>50), %
Trauma at the site of VZV up to 6 m before onset, %
Surgical intervention at the site of rash up to 6 months before onset, %
Site of lesions
Extension of lesions
Missed antiviral prescription
Efficacy of acupuncture and standard analgesic therapy
Comparison of the outcomes of treatments under evaluation.
Standard Therapy (n = 32)
Acupuncture (n = 34)
Mean VAS score at baseline (SD)
Mean VAS score after therapy (SD)
Mean change in VAS score (SD)
Response rate (>=2 VAS units decrease), %
Mean McGill score at baseline (SD)
Mean McGill score after therapy (SD)
Mean change in McGill score (SD)
Post-herpetic neuralgia at 3 months, %
Post-herpetic neuralgia at 6 months, %
Post-herpetic neuralgia at 12 months, %
Mean AUC during follow-up (SD)
Comparison between acupuncture and standard analgesic therapy
No significant differences were observed between the 2 therapeutic approaches in any of the outcomes under consideration (Table 2). Neither the mean reduction in VAS score (p = 0.12) or in McGill score (p = 0.9), nor the response rate (p = 0.8), nor the incidence of PHN after 3 months (p = 0.5), nor the mean AUC (total pain burden) during follow-up (p = 0.4) were significantly different across groups.
As to safety, no serious adverse events (grade 3-4 according to WHO safety scale) related to both treatments were observed in the 2 groups. In addition, none of the patients were hospitalized or died during the 4 week treatment. Finally, none of them discontinued treatment due to drug-related complications or procedure-related discomfort.
Lack of proper efficacy evaluations, adequate statistical power and rational design of the previous studies assessing the role of Acupuncture for Zoster related acute pain is acknowledged [36, 37]. Coghlan reported in 1992 the treatment of a small case series of patients with pain caused either by acute HZ or by PHN, including 4 patients each. Electro-acupuncture alone was used and reported as generally effective, endorsing the opportunity for an exploratory trial . More recently, Ni et al. reported the treatment of 48 cases of HZ by nerve stem puncturing. Among these, all of the 16 cases treated within 1 week from pain onset were reported as cured, in comparison with only 5 (15.6%) among the 32 cases whose pain lasted over 1 week before treatment . This study was based on a consecutive case series and lacked of any control arm . He et al.  described 60 cases of senile HZ treated by encircled acupuncture plus valacyclovir (300 mg twice daily orally for 10 days) versus valacyclovir only. The authors report that patients were divided into 2 well balanced treatment groups, not mentioning any randomization process; no alternative analgesic treatment was administered to the control group . The only significantly different outcome between groups was the duration of acute pain (3.8 days for combined treatment vs 5.5 days for valacyclovir only); furthermore, a lower incidence of pain persistence during follow-up was reported for patients undergoing combined treatment (26.7 vs 53.3%), although no definition was provided neither for PHN nor for the duration of follow-up . Therefore, to our knowledge, this is the first randomized clinical trial assessing the efficacy of acupuncture for the control of HZ-related intense or very intense acute pain as well as for the prevention of PHN during follow-up [30, 32, 33, 36, 37]. We found that both AC and ST, associated with the prescription of antivirals, were efficacious in controlling intense or very intense pain. Importantly, the degree of pain control provided by AC was not significantly different from that of ST.
Pain intensity was evaluated by the most frequently used methods in VZV-related pain studies: VAS, to obtain an easy quantification of pain intensity [38, 39]; McGill Pain Questionnaire to qualifying pain [39–41]. We found no significant difference both in VAS and McGill scores after 4 weeks of treatment between AC and ST. Since pain intensity at rash onset is widely reported as the best predictor of PHN [6, 45–48], having selected for patients with intense or very intense pain we also evaluated the incidence of PHN at 3, 6 and 12 months after rash onset, as well as the total pain burden during follow-up in the 2 study arms. Under the assumption that acupuncture may have an immune modulating activity [49–52], evaluating these endpoint might have revealed an ability of this medical tool to influence the rate of pain persistence and relapses. The incidence of PHN at 3, 6 and 12 months, as well as the mean AUC were overlapping in the 2 arms (Table 2). The limited dimensions of our population do not allow, however, to conclusively exclude, although unlikely, this hypothesis.
It should be noted that the stratification for pain resulted in a perfect match of patients with very intense pain at presentation, which could have otherwise remarkably influenced the validity of our results for all endpoints. Furthermore, the percentage of patients which did not receive antiviral therapy was identical in the 2 arms (15.6% and 17.6%, respectively), protecting our trial from another possible confounding factor, that is a difference in potential control of acute HZ pain by antiviral therapy between groups [1, 53].
This study has some limitations, however, that must be considered in interpreting results. First, we decided to measure pain intensity both by VAS and McGill scales at study entrance and after 4 weeks of treatment, that is when the investigator felt that his intervention for the control of acute pain was complete. Clearly, it would have been interesting to measure ongoing pain control at intermediate time points, to better appreciate minor differences between the investigational arms. This was not feasible, however, due to study budget constraints; in any case, most of the other investigations assessing the efficacy of experimental treatments for pain control were built with very similar or identical designs [54, 55].
Second, our trial was based upon a relatively small sample of treated patients (n = 66). However, 41 GPs and 3 hospital units were committed to recruit HZ patients for 2 years, and more than 400 HZ patients had to be enrolled to identify 129 patients with intense or very intense pain at presentation (those with the highest need of improvements in pain control). In addition, a relatively large number of the eligible patients (n = 27) refused to enter the trial. However, this was probably unavoidable because of distrust or fear of an unusual technique such as acupuncture. Notably, no differences in age, gender and pain intensity were observed between these patients and those included in our analyses. Finally, 28 patients were excluded immediately after randomization because of rapid pain reduction. However, it would clearly have been unethical to enforce these patients in a strong analgesic therapy as well as acupuncture. Notably, and expectedly, the latter patients were younger and had very intense pain in only 2 cases. This is the reason why it would have had very little sense to use an intention-to-treat analysis, which is usually the gold standard analysis for RCTs , in this case. In other terms, the 28 patients with rapid pain reduction represent a separate group of patients, not needing long term analgesic therapy; they therefore may not carry the potential for selection bias. As a final remark on sample size, it should be noted that the results of the 2 interventions were very similar and, using a one-tailed non-inferiority approach, the statistical power of our analysis is acceptable for all outcomes, ranging from a minimum of 81% for the change in VAS score, up to 86% for the change in McGill score.
A third limitation is represented by the lack of both a control arm with short acting analgesics only, and a control arm with mock acupuncture [57–59]. This was beyond our scope because of study budget constraints. However, as the access to alternative drugs and complementary medicine techniques for acute pain control is on the rise in our area and elsewhere in the world, we felt that the design of this nested trial, investigating "real life" differences in therapeutic potential between ST and AC as presently used in severely ill HZ patients, might still add to the knowledge on the analgesic efficacy of acupuncture. Indeed, proper stratification of patients between arms rather than blinding might have influenced the assessment of the efficacy of either intervention, that is taking into account - when distributing patients between arms - the main factors that may influence the efficacy of either intervention, such as age, pain intensity and missed antiviral prescription. These variables were indeed well-matched in our study population. A direct comparison between ST and AC for acute pain in HZ is the object of another three-armed, partially blinded randomized trial, known as ACUZoster, whose design was recently published and which is still ongoing .
With these caveats, our study provides the first evidence from a randomized controlled design of a potential role of acupuncture in the treatment of acute herpetic pain. Patients with intense or very intense pain at presentation showed a significant and similar degree of pain relief using acupuncture and standard pharmacological therapy. Also, no differences between treatments were observed in the incidence of severe adverse events. Given that patients treated with acupuncture carry a lower risk of cumulative drug toxicity, if these findings will be confirmed by the ensuing ACUZoster trial and/or by other investigations, acupuncture might be appropriately considered among the available therapeutic options for the control of severe acute HZ related pain.
Standard Pharmacological Treatment
Visual Analogue Scale
McGill Pain Questionnaire
Area Under the Curve
Post Herpetic Neuralgia
Pain Management Clinic.
This investigation was funded by the Fondazione Onlus Camillo de Lellis per l'Innovazione e la Ricerca in Medicina, Pescara, Italy, and by the Ministry of Health of the Abruzzo Region (protocol n.1269, 30/Nov/2004). Both Institutions granted the unusual opportunity of carrying out a study design completely independent of the influence of pharmaceutical companies; this was motivated by the strive to improve daily assistance to HZ patients and their acute pain. A permanent network was established in our area as a consequence of the study design. We are heavily indebted to Mr. Massimo Franciotti, who assisted us in most of secretarial work throughout the study, together with Mrs. Bianca Zappalorto. Their help was invaluable in tracking patients beyond outpatient visits. We are also indebted to Mrs. Loredana Puglielli, Mrs. Angela Pisciella, and to Mr. Vincenzo Massei, for their precious and constant help with HZ outpatients, and to Mrs. Rosanna D'Amico, for her precious assistance to patients in the PMC clinic. We are grateful to many other nurses, colleagues, students and young Medical Doctors in Pescara General Hospital, who provided us invaluable help and assistance in caring for HZ patients.
The VZV Pain Study Group is composed by the following Medical Doctors in the Pescara Health District: Luana Cosentino, Luigi Clerico, Assunta Manna, Elena Mazzotta, Federica Sozio, Adriana Agostinone, Francesco Di Masi, Carlo Carunchio, Domenico D'Antonio, Valter Armellani, Silvio Basile, Mariapia Blasetti, Loredana Marano, Massimo Calisi, Enzo Di Benedetto, Sergio Finucci, Luciano Cervone, Pasquale Cordoma, Camilla Palombo, Lucio Ciammaricone, Gina Ciccarelli, Moreno D'Emilio, Giuseppe De Filippo, Dino De Sanctis, Enzo De Sanctis, Gianni Di Fermo, Teresa Galante, Alvaro Mazzocchetti, Fabio Panzieri, Sante Pardo, Stefania Plessi, Paolo Primavera, Carlo Santuccione, Renato Seller, Emidio Spazzafumo, Maurizio Todisco, Antonella Legge, Patrizia Rodriguez, Marisa Diodati, Attilio Cupaiolo, Luciana Alterio, Giulio Calella.
- Dworkin RH, Portenoy RK: Pain and its persistence in herpes zoster. Pain. 1996, 67: 241-251. 10.1016/0304-3959(96)03122-3.View ArticlePubMedGoogle Scholar
- Hope-Simpson RE: The Nature of Herpes Zoster: A Long-Term Study and a New Hypothesis. Proc R Soc Med. 1965, 58: 9-20.PubMedPubMed CentralGoogle Scholar
- Johnson RW: The future of predictors, prevention, and therapy in postherpetic neuralgia. Neurology. 1995, 45 (12 Suppl 8): S70-72.View ArticlePubMedGoogle Scholar
- Watson CP, Oaklander AL: Postherpetic neuralgia. Pain Pract. 2002, 2: 295-307. 10.1046/j.1533-2500.2002.02039.x.View ArticlePubMedGoogle Scholar
- Dworkin RH, Gnann JW, Oaklander AL, Raja SN, Schmader KE, Whitley RJ: Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008, 9 (1 Suppl 1): S37-44.View ArticlePubMedGoogle Scholar
- Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K: Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc. 2007, 55: 1168-1175. 10.1111/j.1532-5415.2007.01231.x.View ArticlePubMedGoogle Scholar
- Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH: Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004, 39: 342-348. 10.1086/421942.View ArticlePubMedGoogle Scholar
- Boureau F, Legallicier P, Kabir-Ahmadi M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003, 104: 323-331. 10.1016/S0304-3959(03)00020-4.View ArticlePubMedGoogle Scholar
- Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, et al: Recommendations for the management of herpes zoster. Clin Infect Dis. 2007, 44 (Suppl 1): S1-26.View ArticlePubMedGoogle Scholar
- Mustafa MB, Arduino PG, Porter SR: Varicella zoster virus: review of its management. J Oral Pathol Med. 2009, 38 (9): 673-688. 10.1111/j.1600-0714.2009.00802.x.View ArticlePubMedGoogle Scholar
- Whitley RJ, Volpi A, McKendrick M, Wijck A, Oaklander AL: Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol. 2010, 48 (Suppl 1): S20-28.View ArticlePubMedGoogle Scholar
- Gnann JW, Whitley RJ: Clinical practice. Herpes zoster. N Engl J Med. 2002, 347: 340-346. 10.1056/NEJMcp013211.View ArticlePubMedGoogle Scholar
- Hui F, Cheng A, Chiu M, Vayda E: Integrative approach to the treatment of postherpetic neuralgia: a case series. Altern Med Rev. 1999, 4: 429-435.PubMedGoogle Scholar
- Parruti G, Tontodonati M, Rebuzzi C, Polilli E, Sozio F, Consorte A, Agostinone A, Di Masi F, Congedo G, D'Antonio D, et al: Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy. BMC Med. 2010, 8: 58-10.1186/1741-7015-8-58.View ArticlePubMedPubMed CentralGoogle Scholar
- Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H: Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004, 63: 959-965.View ArticlePubMedGoogle Scholar
- Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M: Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002, 42: 229-236. 10.1016/S0028-3908(01)00172-1.View ArticlePubMedGoogle Scholar
- Johnson RPD: Improving the management of varicella, herpes zoster and zoster-associated pain: recommendations from the IHMF Management Stategies Workshop [online]. [http://www.ihmf.org/library/monograph/m_11.pdf]
- Johnson RW: Herpes zoster in the immunocompetent patient: management of post-herpetic neuralgia. Herpes. 2003, 10: 38-45.PubMedGoogle Scholar
- Schmader K: Herpes zoster in older adults. Clin Infect Dis. 2001, 32: 1481-1486. 10.1086/320169.View ArticlePubMedGoogle Scholar
- Roxas M: Herpes zoster and postherpetic neuralgia: diagnosis and therapeutic considerations. Altern Med Rev. 2006, 11: 102-113.PubMedGoogle Scholar
- Wu CL, Marsh A, Dworkin RH: The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain. 2000, 87: 121-129. 10.1016/S0304-3959(00)00230-X.View ArticlePubMedGoogle Scholar
- Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, Nurmikko T: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010, 17: 1113-e1188. 10.1111/j.1468-1331.2010.02999.x.View ArticlePubMedGoogle Scholar
- Christo PJ, Hobelmann G, Maine DN: Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging. 2007, 24: 1-19. 10.2165/00002512-200724010-00001.View ArticlePubMedGoogle Scholar
- Niv D, Maltsman-Tseikhin A: Postherpetic neuralgia: the never-ending challenge. Pain Pract. 2005, 5: 327-340. 10.1111/j.1533-2500.2005.00035.x.View ArticlePubMedGoogle Scholar
- Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS: Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005, 2: e164-10.1371/journal.pmed.0020164.View ArticlePubMedPubMed CentralGoogle Scholar
- Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, Royall RM, Max MB: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002, 59: 1015-1021.View ArticlePubMedGoogle Scholar
- Galantino ML, Eke-Okoro ST, Findley TW, Condoluci D: Use of noninvasive electroacupuncture for the treatment of HIV-related peripheral neuropathy: a pilot study. J Altern Complement Med. 1999, 5: 135-142. 10.1089/acm.1999.5.135.View ArticlePubMedGoogle Scholar
- Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, Hillman S, Brizz B, Cohn DL: Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 1998, 280: 1590-1595. 10.1001/jama.280.18.1590.View ArticlePubMedGoogle Scholar
- Spacek A, Hanl G, Groiss O, Koinig H, Kress HG: Acupuncture and ganglionic local opioid analgesia in trigeminal neuralgia. Wien Med Wochenschr. 1998, 148: 447-449.PubMedGoogle Scholar
- Coghlan CJ: Herpes zoster treated by acupuncture. Cent Afr J Med. 1992, 38: 466-467.PubMedGoogle Scholar
- Lewith GT, Field J, Machin D: Acupuncture compared with placebo in post-herpetic pain. Pain. 1983, 17: 361-368. 10.1016/0304-3959(83)90167-7.View ArticlePubMedGoogle Scholar
- He Y, Fang R: Treatment of 60 cases of senile herpes zoster by encircled acupuncture plus valaciclovir. J Acupunct Tuina Sci. 2007, 5: 171-173. 10.1007/s11726-007-0171-9.View ArticleGoogle Scholar
- Ni X: Treatment of 48 cases of herpes zoster by puncturing nerve stem. J Acupunct Tuina Sci. 2008, 6: 368-369. 10.1007/s11726-008-0368-6.View ArticleGoogle Scholar
- Rutgers MJ, van Romunde LKJ, Osman PO: A small randomized comparative trial of acupuncture versus transcutaneous electrical neurostimulation in postherpetic neuralgia. Pain Clin. 1988, 2: 87-89.Google Scholar
- Wang S: Treatment of 30 cases of post-herpetic neuralgia by acupuncture combined with point injection. J Acupunct Tuina Sci. 2008, 6: 182-183. 10.1007/s11726-008-0182-1.View ArticleGoogle Scholar
- Peng WN, Liu ZS, Deng YH, Mao M, Yu JN, Du Y: Evaluation of literature quality of acupuncture for treatment of herpes zoster and approach to the laws of treatment. Chinese acupuncture & moxibustion. 2008, 28: 147-150.Google Scholar
- Yu XM, Zhu GM, Chen YL, Fang M, Chen YN: Systematic assessment of acupuncture for treatment of herpes zoster in domestic clinical studies. Chinese acupuncture & moxibustion. 2007, 27: 536-540.Google Scholar
- Hao S, Tian B, Wang L: A primary evaluation of VAS for use in clinical experimentral pain assessment. Zhongguo Yi Xue Ke Yuan Xue Bao. 1994, 16: 397-399.Google Scholar
- Thyregod HG, Rowbotham MC, Peters M, Possehn J, Berro M, Petersen KL: Natural history of pain following herpes zoster. Pain. 2007, 128: 148-156. 10.1016/j.pain.2006.09.021.View ArticlePubMedGoogle Scholar
- Melzack R, Torgerson WS: On the language of pain. Anesthesiology. 1971, 34: 50-59. 10.1097/00000542-197101000-00017.View ArticlePubMedGoogle Scholar
- Melzack R: The McGill pain questionnaire: from description to measurement. Anesthesiology. 2005, 103: 199-202. 10.1097/00000542-200507000-00028.View ArticlePubMedGoogle Scholar
- Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. 2003, Publish Date: August 2009. Last accessed Aug 23, 2010, [http://ctep.cancer.gov]
- Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, et al: Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004, 5: 344-356. 10.1016/j.jpain.2004.06.001.View ArticlePubMedGoogle Scholar
- Garattini S, Bertele V: Non-inferiority trials are unethical because they disregard patients' interests. Lancet. 2007, 370 (9602): 1875-1877. 10.1016/S0140-6736(07)61604-3.View ArticlePubMedGoogle Scholar
- Jung BF, Johnson RW, Griffin DR, Dworkin RH: Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004, 62: 1545-1551.View ArticlePubMedGoogle Scholar
- Opstelten W, Zuithoff NP, van Essen GA, van Loon AM, van Wijck AJ, Kalkman CJ, Verheij TJ, Moons KG: Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain. 2007, 132 (Suppl 1): S52-59.View ArticlePubMedGoogle Scholar
- Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, Breuer J: A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol. 2003, 70 (Suppl 1): S24-30.View ArticlePubMedGoogle Scholar
- Whitley RJ, Weiss HL, Soong SJ, Gnann JW: Herpes zoster: risk categories for persistent pain. J Infect Dis. 1999, 179: 9-15. 10.1086/314562.View ArticlePubMedGoogle Scholar
- Bresler DE, Kroening RJ: Three essential factors in effective acupunture therapy. Am J Chin Med (Gard City N Y). 1976, 4: 81-86. 10.1142/S0192415X76000123.View ArticleGoogle Scholar
- Quirico PE LG, Allais G: L'effetto immunomodulatore dell'agopuntura. G Ital Riflessot Agopunt. 1996, 8: 175-179.Google Scholar
- Yan WK, Wang JH, Chang QQ: Effect of leu-enkephalin in striatum on modulating cellular immune during electropuncture. Sheng Li Xue Bao. 1991, 43: 451-456.PubMedGoogle Scholar
- Yu Y, Kasahara T, Sato T, Guo SY, Liu Y, Asano K, Hisamitsu T: Enhancement of splenic interferon-gamma, interleukin-2, and NK cytotoxicity by S36 acupoint acupuncture in F344 rats. Jpn J Physiol. 1997, 47: 173-178. 10.2170/jjphysiol.47.173.View ArticlePubMedGoogle Scholar
- Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA: Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000, 321: 794-796. 10.1136/bmj.321.7264.794.View ArticlePubMedPubMed CentralGoogle Scholar
- Zheng Z, Guo RJ, Helme RD, Muir A, Da Costa C, Xue CC: The effect of electroacupuncture on opioid-like medication consumption by chronic pain patients: a pilot randomized controlled clinical trial. Eur J Pain. 2008, 12: 671-676. 10.1016/j.ejpain.2007.10.003.View ArticlePubMedGoogle Scholar
- Zin CS, Nissen LM, O'Callaghan JP, Duffull SB, Smith MT, Moore BJ: A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain. 2010, 11: 462-471. 10.1016/j.jpain.2009.09.003.View ArticlePubMedGoogle Scholar
- Schulz KF, Altman DG, Moher D: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010, 11: 32-10.1186/1745-6215-11-32.View ArticlePubMedPubMed CentralGoogle Scholar
- Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR: Acupuncture for tension-type headache. Cochrane Database Syst Rev. 2009, CD007587-Google Scholar
- Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR: Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev. 2009, CD001218-Google Scholar
- Schneider A, Weiland C, Enck P, Joos S, Streitberger K, Maser-Gluth C, Zipfel S, Bagheri S, Herzog W, Friederich HC: Neuroendocrinological effects of acupuncture treatment in patients with irritable bowel syndrome. Complement Ther Med. 2007, 15: 255-263. 10.1016/j.ctim.2006.12.002.View ArticlePubMedGoogle Scholar
- Fleckenstein J, Kramer S, Hoffrogge P, Thoma S, Lang PM, Lehmeyer L, Schober GM, Pfab F, Ring J, Weisenseel P, et al: Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. BMC Complement Altern Med. 2009, 9: 31-10.1186/1472-6882-9-31.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/11/46/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.